Literature DB >> 22624908

Corneal collagen crosslinking in vitro: inhibited regeneration of human limbal epithelial cells after riboflavin-ultraviolet-A exposure.

Andreas Thorsrud1, Bjørn Nicolaissen, Liv Drolsum.   

Abstract

PURPOSE: To assess the hypothesis that during corneal crosslinking (CXL) treatment, riboflavin and ultraviolet-A (UVA) may have a toxic effect on human limbal epithelial cells.
SETTING: Center for Eye Research, Department of Ophthalmology, Oslo University Hospital Ullevål, Oslo, Norway.
DESIGN: Experimental study.
METHODS: In this vitro study, limbal biopsies from corneoscleral rims collected after corneal transplantation were treated with the following combinations: riboflavin-UVA, riboflavin only, or UVA only; a control group received no treatment. After 3 weeks of cell culture, outgrowth of epithelium from the biopsies was evaluated by measuring the area of cell expansion and the number of cell layers. The explanted biopsies were analyzed for proliferation using immunohistochemistry marker Ki-67 and for apoptosis using the terminal deoxynucleotidyl transferase deoxy-UTP-nick end labeling (TUNEL) assay.
RESULTS: The mean outgrowth from the biopsies was 2.25 mm(2) ± 6.90 (SD) in the riboflavin-UVA group, 181.4 ± 94.8 mm(2) in the riboflavin-only group, 128.5 ± 129.5 mm(2) in the UVA-only group, and 176.2 ± 114.0 mm(2) in the control group. There were no statistically significant between-group differences in the number of cell layers except in the riboflavin-UVA group, in which no cells were found. Detection of apoptosis with the TUNEL-assay was found in the riboflavin-UVA group only (4/5 sections). The proliferation marker Ki-67 was positive in some sections in all groups.
CONCLUSION: Cytotoxicity and reduced cell expansion of human limbal epithelial cells occurred after riboflavin-UVA treatment in vitro, emphasizing the importance of avoiding riboflavin-UVA on the limbus during CXL.
Copyright © 2012 ASCRS and ESCRS. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22624908     DOI: 10.1016/j.jcrs.2011.12.038

Source DB:  PubMed          Journal:  J Cataract Refract Surg        ISSN: 0886-3350            Impact factor:   3.351


  7 in total

Review 1.  [Complications of corneal cross-linking].

Authors:  T G Seiler; G Schmidinger; I Fischinger; T Koller; T Seiler
Journal:  Ophthalmologe       Date:  2013-07       Impact factor: 1.059

2.  Deep anterior lamellar keratoplasty in eyes previously treated with collagen crosslinking for keratoconus: 3-year results.

Authors:  Anıl Kubaloglu; Esin Sogutlu Sari; Arif Koytak
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2020-01-08       Impact factor: 3.117

Review 3.  Corneal pain and experimental model development.

Authors:  Tina B McKay; Yashar Seyed-Razavi; Chiara E Ghezzi; Gabriela Dieckmann; Thomas J F Nieland; Dana M Cairns; Rachel E Pollard; Pedram Hamrah; David L Kaplan
Journal:  Prog Retin Eye Res       Date:  2018-11-16       Impact factor: 21.198

4.  Influence of standard corneal cross-linking in keratoconus patients on macular profile.

Authors:  Mohammad Mirzaei; Masood Bagheri; Arash Taheri
Journal:  J Curr Ophthalmol       Date:  2018-06-29

5.  Long-Term Follow-Up of Accelerated Transepithelial Corneal Crosslinking for Post-LASIK Ectasia: A Pilot Prospective Observational Study.

Authors:  Mi Tian; Xiaoyu Zhang; Weijun Jian; Ling Sun; Yang Shen; Xingtao Zhou
Journal:  Front Bioeng Biotechnol       Date:  2021-12-22

Review 6.  Potential Effects of Corneal Cross-Linking upon the Limbus.

Authors:  Johnny E Moore; Davide Schiroli; C B Tara Moore
Journal:  Biomed Res Int       Date:  2016-09-05       Impact factor: 3.411

7.  Protection of Corneal Limbus from Riboflavin Prevents Epithelial Stem Cell Loss after Collagen Cross-Linking.

Authors:  Hyo Kyung Lee; Jin Suk Ryu; Hyun Jeong Jeong; Mee Kum Kim; Joo Youn Oh
Journal:  J Ophthalmol       Date:  2018-06-03       Impact factor: 1.909

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.